ResMed's $69 mil. MAP Acquisition Builds European SDB Market Presence
This article was originally published in The Gray Sheet
Executive Summary
ResMed stands to triple its sales of sleep-disordered breathing (SDB) products in Germany through the $69 mil. cash/debt purchase of Munich-based MAP Medizin-Technologie GmbH, announced Feb. 19.